Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0KJDY)

Drug Name
LY2801653 Drug Info
Synonyms
Merestinib; LY2801653; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N
Indication
Disease Entry ICD 11 Status REF
Biliary tract cancer 2C17 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Cross-matching ID
PubChem CID
44603533
CAS Number
CAS 1206799-15-6
TTD Drug ID
DM0KJDY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Proto-oncogene c-Met (MET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [4]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [5]
Amivantamab DMZ7AMY Non-small-cell lung cancer 2C25 Approved [6]
Capmatinib DMYCXKL Non-small-cell lung cancer 2C25.Y Approved [7]
Tepotinib DMUQ0E8 Non-small-cell lung cancer 2C25 Approved [8]
RG3638 DMTQJE0 Gastric adenocarcinoma 2B72 Phase 3 [9]
Savolitinib DMALFKX Renal cell carcinoma 2C90 Phase 3 [1]
Beperminogene perplasmid DM6RWBN Critical limb ischemia BD4Y Phase 3 [10]
Tivantinib DMNVP8Q Hepatocellular carcinoma 2C12.02 Phase 3 [11]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Protein kinase (PK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [1]
MGCD265 DMRPCF2 Non-small-cell lung cancer 2C25.Y Phase 2 [1]
ENMD-2076 DMJZVPB Acute myeloid leukaemia 2A60 Phase 2 [1]
RV-568 DM652CM Asthma CA23 Phase 2 [12]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [13]
LX-7101 DM2LYIN Glaucoma/ocular hypertension 9C61 Phase 1/2 [14]
Cyclocreatine DM1I7UO Virus infection 1A24-1D9Z Discontinued in Phase 1 [15]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase (PK) TTU8W4S NOUNIPROTAC Inhibitor [1]
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Modulator [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01285037) A Study of LY2801653 in Advanced Cancer. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Eli Lilly.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Clinical pipeline report, company report or official report of Exelixis (2011).
6 Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
10 Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
12 Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10.
15 Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate. Biochim Biophys Acta. 1989 Oct 19;998(3):317-20.